Xenon Pharmaceuticals (XENE) Gains from Investment Securities (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Gains from Investment Securities of $400000.0 for Q1 2026, down 96.69% year-over-year from $12.1 million in Q1 2025, and up 2322.22% quarter-over-quarter from -$18000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Gains from Investment Securities data on file, last reported at $400000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $400000.0, down 96.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.8 million (up 154.6% YoY), and the FY2025 annual result was $11.1 million, up 3.41% from the prior year.
- Gains from Investment Securities rose to $400000.0 in Q1 2026 per XENE's latest filing, from -$18000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $30.4 million in Q4 2024 and troughed at -$18000.0 in Q4 2025.
- A 5-year average of $7.1 million and a median of $7.1 million in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities jumped 42069.97% in 2023, then slumped 100.06% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $7.1 million in 2022, then plunged by 64.28% to $2.5 million in 2023, then jumped by 1096.32% to $30.4 million in 2024, then sank by 100.06% to -$18000.0 in 2025, then jumped by 2322.22% to $400000.0 in 2026.
- Business Quant data shows XENE's Gains from Investment Securities at $400000.0 in Q1 2026, -$18000.0 in Q4 2025, and $11.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | -18,000.00 |
| Dec 31, 2025 | -18,000.00 |
| Sep 30, 2025 | 11.18 Mn |
| Sep 30, 2025 | 11.18 Mn |
| Jun 30, 2025 | 11.68 Mn |
| Jun 30, 2025 | 11.68 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2024 | 30.42 Mn |
| Dec 31, 2024 | 30.42 Mn |
| Sep 30, 2024 | 11.01 Mn |
| Sep 30, 2024 | 11.01 Mn |
| Jun 30, 2024 | 50,254.00 |
| Jun 30, 2024 | 50,254.00 |
| Dec 31, 2023 | 2.54 Mn |
| Dec 31, 2023 | 2.54 Mn |
| Sep 30, 2023 | 9.01 Mn |
| Sep 30, 2023 | 9.01 Mn |